Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > BioSante Pharmaceuticals Announces Results

August 16th, 2004

BioSante Pharmaceuticals Announces Results

Abstract:
BioSante reported a net loss of approximately $2.6 million (or $0.15 per share) for the quarter, compared to a net loss of approximately $1.6 million (or $0.18 per share) for the same period in 2003. The increased total net loss was due primarily to increased expenses related to development of the company's hormone therapy products, including the ongoing Phase III clinical trial of Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of menopausal symptoms.

Source:
Businesswire

Bookmark:

Related News Press

Financial Reports

Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013

Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013

Arrowhead Reports Fiscal 2013 Second Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time May 9th, 2013

Arrowhead to Report Fiscal 2013 Second Quarter Financial Results - Conference Call Scheduled for Thursday, May 9, 2013 May 2nd, 2013